Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval
(Bloomberg) -- Emergent BioSolutions Inc. led an advance in the stocks of companies working on vaccines and antiviral products this week as investors await word from US regulators on if its smallpox vaccine can also be used for the fast-spreading mpox virus. Most Read from BloombergManchester Is Giving London a Run for Its MoneyBoston’s Broke and Broken Transit System Hurts Downtown RecoveryA Floating Island in Baltimore Raises Hope for a Waterfront RevivalA Warehouse Store Promises Housing for